{
    "clinical_study": {
        "@rank": "30188", 
        "arm_group": {
            "arm_group_label": "dose escalation then expansion", 
            "arm_group_type": "Experimental", 
            "description": "Dose escalation of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg. Six dose levels are planned: level 1,0.1 mg/kg; level 2,0.3 mg/kg; level 3, 1.0 mg/kg; level 4,3.0 mg/kg; level 5,10 mg/kg; level 6,20 mg/kg.\nDose Expansion - Up to 20 subjects will be enrolled and treated at the dose determined in Dose Escalation arm."
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, sequential dose escalation and expansion study to evaluate the\n      safety, tolerability, and pharmacokinetics of DS-8895a in Japanese subjects with advanced\n      solid tumors."
        }, 
        "brief_title": "Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced solid tumor that is refractory to standard treatment, or for which no\n             standard treatment is available.\n\n          -  Eastern Cooperative Oncology Group performance status(PS) of 0 or 1\n\n        Exclusion Criteria:\n\n          -  Have any of the following concomitant disease or had the history of having following\n             disease within 6 months before enrollment:\n\n        Cardiac failure (NYHA \u2265 ClassIII), myocardial infarction, cerebral infarction, unstable\n        angina, arrhythmia requiring treatment, coronary-artery/peripheral artery bypass surgery,\n        cerebrovascular disease, pulmonary thromboembolism, deep-vein thrombosis or clinically\n        severe thromboembolic event, or clinically severe pulmonary disease (eg, interstitial\n        pneumonia, pulmonary fibrosis,  radiation pneumonia, drug induced pneumonia)\n\n          -  Severe or uncontrolled concomitant disease.\n\n          -  Clinically active brain metastases defined as symptomatic or requiring treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004717", 
            "org_study_id": "DS8895-A-J101"
        }, 
        "intervention": {
            "arm_group_label": "dose escalation then expansion", 
            "intervention_name": "DS-8895a", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "advanced solid tumor", 
            "Phase 1", 
            "Oncology"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kashiwa", 
                    "country": "Japan", 
                    "state": "Chiba", 
                    "zip": "277-8577"
                }, 
                "name": "National Cancer Center Hospital East"
            }, 
            "investigator": {
                "last_name": "Kohei Shitara, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-8895a in Subjects With Advanced Solid Tumors", 
        "overall_contact": {
            "email": "ishida.marie.fm@daiichisankyo.co.jp", 
            "last_name": "Marie Shiga", 
            "phone": "81-3-5740-3792"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "to investigate the safety of DS-8895a reporting on frequency and seriousness of treatment emergent adverse events", 
                "measure": "number of participants experiencing dose limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "day 1 through day 28"
            }, 
            {
                "description": "to investigate the safety of DS-8895a reporting on frequency and seriousness of treatment emergent adverse events", 
                "measure": "number of participants experiencing clinical or laboratory adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "from start of treatment to end of treatment, on expected average 12 weeks"
            }, 
            {
                "description": "pharmacokinetics (Area Under the Curve-AUC, Terminal Elimination half-life-t1/2, Total Body Clearance) of DS-8895a in Japanese subjects with advanced solid tumors, and also to investigate the recommended dose of DS-8895a for subsequent clinical studies", 
                "measure": "serum pharmacokinetics of DS-8895a", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 - days 1, 2, 4, 8 and 15; Cycle 2-days 1, 2, 4, 8 and 15; Cycle 3 and on- days 1; end of study; 45 days post last dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Human anti-human antibody (HAHA) profile for DS-8895a [Time Frame: Cycle 1 - days 1, and 15; Cycle 2 and on - days 1; end of study; 45 days post last dose] The presence of HAHA (anti-DS-8895a neutralizing antibody) in serum will be assessed\"", 
                "measure": "level of anti-DS-8895a (HAHA) antibody", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 days 1 and 15; Cycle 2 day 1; end of study; 45 days post-last-dose"
            }, 
            {
                "description": "proportion of subjects with the best overall response of stable disease or better will be measured every 6 weeks until study drug discontinued.", 
                "measure": "disease control rate", 
                "safety_issue": "No", 
                "time_frame": "every 6 weeks"
            }, 
            {
                "description": "effects on blood will be determined at day 1 and 2 of each cycle", 
                "measure": "pharmacodynamic effects in blood", 
                "safety_issue": "No", 
                "time_frame": "day 1 and 2"
            }, 
            {
                "description": "effects on tumor cells will be determined after each 15 day cycle", 
                "measure": "pharmacodynamic effects in tumors", 
                "safety_issue": "No", 
                "time_frame": "baseline and day 1 of every cycle"
            }, 
            {
                "description": "sum of complete response and partial response rates measured every 6 weeks until study drug discontinuation", 
                "measure": "objective response rate", 
                "safety_issue": "No", 
                "time_frame": "every 6 weeks"
            }
        ], 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}